Novità nelle cure
Paclitaxel ed ipertermia contro il cancro al seno
La presente esperienza su cellule tumorali di carcinoma mammario evidenzia come l'ipertermia sinergizza con il paclitaxel sensibilizzando le cellule verso l'azione del chemioterapico. Una importante evidenza nella lotta contro il cancro.
Dr. Carlo Pastore
Biol Pharm Bull. 2012 Dec 11. [Epub ahead of print]
Department of First Chemotherapy, Affiliated Cancer Hospital of Guangxi Medical University.
As a physical adjuvant approach in the treatment of solid tumors, regional hyperthermia plays a synergistic role in enhancing the efficacy of simultaneous chemotherapy. Paclitaxel (PTX) is an anti-mitotic taxane drug that is widely used in chemotherapy for the treatment of various human malignancies such as lung, ovarian, breast, and head and neck cancers. Since the possibility that hyperthermia can enhance the anti-tumor effects of PTX has not yet been investigated, the present study was designed to evaluate the effects of short-term hyperthermia on PTX-induced antitumor activity in the human breast cancer line MCF-7. It was found that short-term hyperthermia promoted PTX-induced suppression of cell proliferation. The IC(50) for PTX was reduced from 18.2 ± 1.0 to 15.0± 0.45 nM (P<0.05). The level of PTX-induced cell apoptosis was increased from 8.5 ± 1.2 to 16.4 ± 2.4% (P<0.05) and from 15.2 ± 1.4 to 34.9 ±2.8% (P<0.05), at the end of the first and second hyperthermia cycles, respectively; both the activity and expression of caspase-7 were enhanced. In addition, PTX-induced cell cycle arrest in the G2/M phase was further promoted by short-term hyperthermia, from 9.3 ± 0.7 to 12.5 ± 0.9% (P<0.05). In contrast, short-term hyperthermia affected neither tumor cell migration nor invasion in the presence or absence of PTX. The presented data thus suggest that short-term hyperthermia may serve as a feasible approach in the promotion of breast cancer cell sensitivity to PTX.